About

USPTO Says AIA Patent Reviews Are for First-Run Challenges, Not Repeat Litigation

Published
Score
11

Why it matters

On May 14, 2026, the USPTO Director issued a precedential decision denying institution of an inter partes review petition in Magnolia Medical Technologies, Inc. v. Kurin, Inc., involving U.S. Patent No. 12,138,052 B1. The ruling reframed the statutory purpose of AIA reviews: they exist as an alternative to district-court litigation, not as a second forum after a party has already litigated and lost. Magnolia had challenged the patent's validity in district court, failed, and then filed an IPR petition at the Patent Trial and Appeal Board. The Director rejected the petition, holding that the Leahy-Smith America Invents Act created IPR and post-grant review to provide a streamlined administrative path to validity testing—not to relitigate issues already decided by courts.

The decision rests on the Director's view that Magnolia's petition followed rather than replaced its district-court case. The absence of a jury verdict on certain invalidity theories did not, in the Director's analysis, justify reopening those theories at the USPTO. The specific contours of the Director's reasoning and any factual distinctions the petitioner raised remain undisclosed.

Patent challengers should treat this as a warning. The ruling signals that the USPTO will police the boundary between litigation and AIA review with real teeth, blocking petitions that appear designed to harass patent owners or circumvent adverse court judgments. Companies considering PTAB challenges after losing in district court now face a material risk of dismissal on discretionary-denial grounds. Patent owners, conversely, have a new tool to block repeat attacks. The precedential status of the decision means it will shape PTAB practice going forward.

mail Subscribe to Intellectual Property email updates

Primary sources. No fluff. Straight to your inbox.

Also on LawSnap